Expression of CHD5 May Serve As an Independent Biomarker of Prognosis in Colorectal Cancer Via Immunohistochemical Staining

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2020 Jan 16

PMID 31938397

Authors

Yong Zhou

Yi-Er Qiu

Shao-Lan Qin

Yang Luo

Ran Cui

Jun Qin

Jian-Jun Chen

Min-Hao Yu

Ming Zhong

Xing-Yao Shi

Affiliations

Soon will be listed here.

Abstract

Chromodomain helicase DNA binding protein 5 (CHD5) acts as a tumor suppressor in various types of cancer and belongs to CHD protein family. However, no prognostic role for CHD5 has yet been indicated in colorectal cancer. Therefore, the aim of this study was to investigate a possible association between CHD5 expression and colorectal cancer prognosis. Furthermore, immunochemistry was used to investigate CHD5 expression in 310 CRC tissue specimens. Expression of CHD5 significantly positively correlated with the lymphatic metastasis (P=0.007). The prognostic value of CHD5 in relation to overall survival was analyzed by Kaplan-Meier analysis and Cox proportional hazard models. The mean and medium follow-up times after surgery were 5.5 and 6.6 years, respectively. A total of 150 patients died during the 13 years of follow-up in the survey period. We also demonstrated that overall survival was poor in CRC patients with low expression of CHD5 (P=0.003). Accordingly, multivariate analysis identified low CHD5 expression as an independent risk factor (P=0.014), especially in elderly patients or those with late stage cancers. We suggest that CHD5 could serve as an independent prognostic biomarker for colorectal patients. This finding also should be verified by other research groups.

References

Imyanitov E, Birrell G, Filippovich I, Sorokina N, Arnold J, Mould M . Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target. Oncogene. 1999; 18(32):4640-2. DOI: 10.1038/sj.onc.1202863. View

Stanley F, Moore S, Goodarzi A . CHD chromatin remodelling enzymes and the DNA damage response. Mutat Res. 2013; 750(1-2):31-44. DOI: 10.1016/j.mrfmmm.2013.07.008. View

Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D . CHD5 is a tumor suppressor at human 1p36. Cell. 2007; 128(3):459-75. DOI: 10.1016/j.cell.2006.11.052. View

Nenoff P, Kruger C, Ginter-Hanselmayer G, Tietz H . Mycology - an update. Part 1: Dermatomycoses: causative agents, epidemiology and pathogenesis. J Dtsch Dermatol Ges. 2014; 12(3):188-209. DOI: 10.1111/ddg.12245. View

Brenner H, Kloor M, Pox C . Colorectal cancer. Lancet. 2013; 383(9927):1490-1502. DOI: 10.1016/S0140-6736(13)61649-9. View

Garcia I, Mayol G, Rodriguez E, Sunol M, Gershon T, Rios J . Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol Cancer. 2010; 9:277. PMC: 2992029. DOI: 10.1186/1476-4598-9-277. View

Letellier E, Schmitz M, Ginolhac A, Rodriguez F, Ullmann P, Qureshi-Baig K . Loss of Myosin Vb in colorectal cancer is a strong prognostic factor for disease recurrence. Br J Cancer. 2017; 117(11):1689-1701. PMC: 5729446. DOI: 10.1038/bjc.2017.352. View

Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N . CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med. 2016; 374(3):211-22. PMC: 4784450. DOI: 10.1056/NEJMoa1506597. View

Cai C, Ashktorab H, Pang X, Zhao Y, Sha W, Liu Y . MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLoS One. 2012; 7(1):e29750. PMC: 3250477. DOI: 10.1371/journal.pone.0029750. View

10.

Kim M, Chung N, Kang M, Yoo N, Lee S . Genetic and expressional alterations of CHD genes in gastric and colorectal cancers. Histopathology. 2011; 58(5):660-8. DOI: 10.1111/j.1365-2559.2011.03819.x. View

11.

Sawada G, Ueo H, Matsumura T, Uchi R, Ishibashi M, Mima K . CHD8 is an independent prognostic indicator that regulates Wnt/β-catenin signaling and the cell cycle in gastric cancer. Oncol Rep. 2013; 30(3):1137-42. DOI: 10.3892/or.2013.2597. View

12.

Thompson P, Gotoh T, Kok M, White P, Brodeur G . CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene. 2003; 22(7):1002-11. DOI: 10.1038/sj.onc.1206211. View

13.

Ma Z, Song J, Liu S, Han L, Chen Y, Wang Y . Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation. Oncol Lett. 2016; 12(5):4021-4026. PMC: 5104224. DOI: 10.3892/ol.2016.5147. View

14.

Wong R, Chan L, Tsang T, Lee C, Cheung T, Yim S . CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer. Gynecol Obstet Invest. 2011; 72(3):203-7. DOI: 10.1159/000323883. View

15.

Baykara O, Tansarikaya M, Bulut P, Demirkaya A, Buyru N . CHD5 is a potential tumor suppressor in non small cell lung cancer (NSCLC). Gene. 2017; 618:65-68. DOI: 10.1016/j.gene.2017.04.010. View

16.

Xia L, Huang W, Bellani M, Seidman M, Wu K, Fan D . CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes. Cancer Cell. 2017; 31(5):653-668.e7. PMC: 5587180. DOI: 10.1016/j.ccell.2017.04.005. View

17.

Fatemi M, Paul T, Brodeur G, Shokrani B, Brim H, Ashktorab H . Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages. Cancer. 2013; 120(2):172-80. PMC: 3947327. DOI: 10.1002/cncr.28316. View

18.

Kolla V, Zhuang T, Higashi M, Naraparaju K, Brodeur G . Role of CHD5 in human cancers: 10 years later. Cancer Res. 2014; 74(3):652-8. PMC: 3965582. DOI: 10.1158/0008-5472.CAN-13-3056. View